Accession Number : ADA534583


Title :   High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection


Descriptive Note : Journal article


Corporate Author : ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD INTEGRATED TOXICOLOGY DIVISION


Personal Author(s) : Michelow, Ian C ; Lear, Calli ; Scully, Corinne ; Prugar, Laura I ; Longley, Clifford B ; Yantosca, L M ; Ji, Xin ; Karpel, Marshall ; Brudner, Matthew ; Takahashi, Kazue ; Spear, Gregory T ; Alan, ; Ezekpwitz, B ; Schmidt, Emmett V ; Olinger, Gene G


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a534583.pdf


Report Date : Jun 2010


Pagination or Media Count : 6


Abstract : Mannose-binding lectin (MBL) targets diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface glycans. Although recombinant human MBL (rhMBL) trials have focused on reconstitution therapy, safety studies have identified no barriers to its use at higher levels. Ebola viruses cause fatal hemorrhagic fevers for which no treatment exists and that are feared as potential biothreat agents. We found that mice whose rhMBL serum concentrations were increased 7- fold above average human levels survived otherwise fatal Ebola virus infections and became immune to virus rechallenge. Because Ebola glycoproteins potentially model other glycosylated viruses, rhMBL may offer a novel broadspectrum antiviral approach. Circulating mannose-binding lectin (MBL) is a first-line host defense against a wide range of viral and other pathogens. MBL is a C-type lectin that recognizes hexose sugars including mannose, glucose, fucose, and N-acetylglucosamine on the surface of many pathogens. It does not recognize the terminal carbohydrates galactose and sialic acid on normal host cells. Therefore, MBL preferentially recognizes glycosylated viruses including influenza virus, human immunodeficiency virus, severe acute respiratory syndrome coronovirus (SARS-CoV), Ebola virus, and Marburg virus. It also recognizes many glycosylated grampositive and gram-negative bacteria [1, 2]. As a result of common genetic variants, MBL serum levels in humans range from 0 to 10,000 ng/mL. Thirty percent of the human population has levels ,500 ng/mL, which are associated with increased susceptibility to infections in children and immunocompromised individuals [3].


Descriptors :   *EBOLA VIRUS , *ANTIVIRAL AGENTS , *PATHOGENIC MICROORGANISMS , *INFECTIOUS DISEASES , *HOSTS(BIOLOGY) , *HEMORRHAGIC FEVERS , CARBOHYDRATES , GENETICS , CONCENTRATION(CHEMISTRY) , CHILDREN , INFLUENZA VIRUS , GLUCOSE , RETICULOENDOTHELIAL SYSTEM , SIALIC ACIDS , ARBOVIRUSES , MANNOSE , HUMAN IMMUNODEFICIENCY VIRUSES , VIRUS DISEASES , BLOOD SERUM , RESPIRATORY SYSTEM , SAFETY , REPRINTS , SIGNS AND SYMPTOMS


Subject Categories : Medicine and Medical Research
      Microbiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE